Related Experiment Video

Updated: Apr 6, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban

Shawn King1, Marintha Short1, Cassidy Harmon1

  • 1Pharmacy, Saint Joseph Hospital, Lexington, KY, USA.

Vascular Pharmacology
|July 19, 2015
PubMed

Insights

Glycoprotein IIb/IIIa inhibitors are crucial for reducing thrombotic events in acute coronary syndrome. A high-dose regimen of tirofiban now matches the effectiveness of other agents, offering a valuable treatment option.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Glycoprotein (GP) IIb/IIIa inhibitors are vital in managing acute coronary syndrome by inhibiting platelet aggregation.
  • These agents are primarily used in patients with intracoronary thrombus.

Purpose of the Study:

  • To review the pharmacological properties of approved GP IIb/IIIa inhibitors.
  • To examine clinical trials and current guideline recommendations for these agents.

Main Methods:

  • Review of pharmacological data for tirofiban, eptifibatide, and abciximab.
  • Analysis of key clinical trials evaluating GP IIb/IIIa inhibitor efficacy.
  • Assessment of current clinical practice guidelines.

Main Results:

  • All three approved GP IIb/IIIa inhibitors (tirofiban, eptifibatide, abciximab) demonstrate rapid onset and are often used with heparin.
  • Tirofiban's re-emergence with a high-dose bolus regimen shows efficacy comparable to other agents.
  • Unique pharmacological profiles exist for each agent.

Conclusions:

  • GP IIb/IIIa inhibitors remain essential in acute coronary syndrome management.
  • High-dose tirofiban offers an effective treatment alternative.
  • Understanding agent-specific properties is key for optimal patient care.

Keywords:
Abciximab (ab-SIKS-ih-mab)Eptifibatide (ep-ti-FIB-ih-tide)Tirofiban (tye-roe-FYE-ban)

More Related Videos

Engineering Antiviral Agents via Surface Plasmon Resonance13:00

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

2.9K
Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells10:10

Platelet Adhesion and Aggregation Under Flow using Microfluidic Flow Cells

Published on: October 27, 2009

18.8K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
32
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466